BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35436984)

  • 1. B-cell lymphoma 6 alleviates nonalcoholic fatty liver disease in mice through suppression of fatty acid transporter CD36.
    Zhang H; Li Y; Zhang C; Huang K; Zhao J; Le S; Jiang L; Liu H; Yang P; Xiao X; Yu J; Wu J; Ye P; Xia J
    Cell Death Dis; 2022 Apr; 13(4):359. PubMed ID: 35436984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPR40 deficiency is associated with hepatic FAT/CD36 upregulation, steatosis, inflammation, and cell injury in C57BL/6 mice.
    Lu Z; Li Y; Syn WK; Li AJ; Ritter WS; Wank SA; Lopes-Virella MF; Huang Y
    Am J Physiol Endocrinol Metab; 2021 Jan; 320(1):E30-E42. PubMed ID: 33103454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
    Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
    EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ablation of cytochrome P450 omega-hydroxylase 4A14 gene attenuates hepatic steatosis and fibrosis.
    Zhang X; Li S; Zhou Y; Su W; Ruan X; Wang B; Zheng F; Warner M; Gustafsson JÅ; Guan Y
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3181-3185. PubMed ID: 28270609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolactin improves hepatic steatosis via CD36 pathway.
    Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
    J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocyte-Specific Disruption of CD36 Attenuates Fatty Liver and Improves Insulin Sensitivity in HFD-Fed Mice.
    Wilson CG; Tran JL; Erion DM; Vera NB; Febbraio M; Weiss EJ
    Endocrinology; 2016 Feb; 157(2):570-85. PubMed ID: 26650570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice.
    Chikada H; Ida K; Nishikawa Y; Inagaki Y; Kamiya A
    Sci Rep; 2020 Jun; 10(1):9704. PubMed ID: 32546802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P2Y2R Deficiency Ameliorates Hepatic Steatosis by Reducing Lipogenesis and Enhancing Fatty Acid β-Oxidation through AMPK and PGC-1α Induction in High-Fat Diet-Fed Mice.
    Dusabimana T; Park EJ; Je J; Jeong K; Yun SP; Kim HJ; Kim H; Park SW
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 1,2,3,4,6 penta-O-galloyl-β-D-glucose ameliorates high-fat diet-induced nonalcoholic fatty liver disease and maintains the expression of genes involved in lipid homeostasis in mice.
    Kant R; Lu CK; Nguyen HM; Hsiao HH; Chen CJ; Hsiao HP; Lin KJ; Fang CC; Yen CH
    Biomed Pharmacother; 2020 Sep; 129():110348. PubMed ID: 32554245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-β1 pathway: therapeutic role of roflumilast.
    Tao X; He H; Peng J; Xu R; Fu J; Hu Y; Li L; Yang X; Feng X; Zhang C; Zhang L; Yu X; Shen A; Huang K; Fu Q
    Pharmacol Res; 2022 Jan; 175():106004. PubMed ID: 34826603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [KLF9 regulates hepatic lipid metabolism via inducing CD36 expression].
    Zhou SS; Zhang YL; Chang YS
    Sheng Li Xue Bao; 2021 Oct; 73(5):772-780. PubMed ID: 34708234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice.
    Wang X; Ren Q; Wu T; Guo Y; Liang Y; Liu S
    Mol Med Rep; 2014 Dec; 10(6):2917-23. PubMed ID: 25310357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of GPR40 in LDL receptor-deficient mice exacerbates high-fat diet-induced hyperlipidemia and nonalcoholic steatohepatitis.
    Lu Z; Li Y; Li AJ; Syn WK; Wank SA; Lopes-Virella MF; Huang Y
    PLoS One; 2022; 17(11):e0277251. PubMed ID: 36331958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulated microRNA-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease.
    Liu X; Chen S; Zhang L
    Am J Physiol Endocrinol Metab; 2020 Jul; 319(1):E34-E42. PubMed ID: 32228319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance.
    Steneberg P; Sykaras AG; Backlund F; Straseviciene J; Söderström I; Edlund H
    J Biol Chem; 2015 Jul; 290(31):19034-43. PubMed ID: 26085100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigating dual inhibition of ACC and CD36 for the treatment of nonalcoholic fatty liver disease in mice.
    Devereux CJ; Bayliss J; Keenan SN; Montgomery MK; Watt MJ
    Am J Physiol Endocrinol Metab; 2023 Feb; 324(2):E187-E198. PubMed ID: 36629823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing.
    Zeng H; Qin H; Liao M; Zheng E; Luo X; Xiao A; Li Y; Chen L; Wei L; Zhao L; Ruan XZ; Yang P; Chen Y
    Mol Metab; 2022 Mar; 57():101428. PubMed ID: 34974159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel role for the dioxin receptor in fatty acid metabolism and hepatic steatosis.
    Lee JH; Wada T; Febbraio M; He J; Matsubara T; Lee MJ; Gonzalez FJ; Xie W
    Gastroenterology; 2010 Aug; 139(2):653-63. PubMed ID: 20303349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic STAMP2 alleviates high fat diet-induced hepatic steatosis and insulin resistance.
    Kim HY; Park SY; Lee MH; Rho JH; Oh YJ; Jung HU; Yoo SH; Jeong NY; Lee HJ; Suh S; Seo SY; Cheong J; Jeong JS; Yoo YH
    J Hepatol; 2015 Aug; 63(2):477-85. PubMed ID: 25646886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C.
    Miquilena-Colina ME; Lima-Cabello E; Sánchez-Campos S; García-Mediavilla MV; Fernández-Bermejo M; Lozano-Rodríguez T; Vargas-Castrillón J; Buqué X; Ochoa B; Aspichueta P; González-Gallego J; García-Monzón C
    Gut; 2011 Oct; 60(10):1394-402. PubMed ID: 21270117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.